Colorectal cancer incidence, mortality, and stage distribution in European countries in the colorectal cancer screening era: an international population-based study.


Journal

The Lancet. Oncology
ISSN: 1474-5488
Titre abrégé: Lancet Oncol
Pays: England
ID NLM: 100957246

Informations de publication

Date de publication:
07 2021
Historique:
received: 26 01 2021
revised: 29 03 2021
accepted: 30 03 2021
pubmed: 29 5 2021
medline: 13 7 2021
entrez: 28 5 2021
Statut: ppublish

Résumé

Colorectal cancer screening programmes and uptake vary substantially across Europe. We aimed to compare changes over time in colorectal cancer incidence, mortality, and stage distribution in relation to colorectal cancer screening implementation in European countries. Data from nearly 3·1 million patients with colorectal cancer diagnosed from 2000 onwards (up to 2016 for most countries) were obtained from 21 European countries, and were used to analyse changes over time in age-standardised colorectal cancer incidence and stage distribution. The WHO mortality database was used to analyse changes over time in age-standardised colorectal cancer mortality over the same period for the 16 countries with nationwide data. Incidence rates were calculated for all sites of the colon and rectum combined, as well as the subsites proximal colon, distal colon, and rectum. Average annual percentage changes (AAPCs) in incidence and mortality were estimated and relevant patterns were descriptively analysed. In countries with long-standing programmes of screening colonoscopy and faecal tests (ie, Austria, the Czech Republic, and Germany), colorectal cancer incidence decreased substantially over time, with AAPCs ranging from -2·5% (95% CI -2·8 to -2·2) to -1·6% (-2·0 to -1·2) in men and from -2·4% (-2·7 to -2·1) to -1·3% (-1·7 to -0·9) in women. In countries where screening programmes were implemented during the study period, age-standardised colorectal cancer incidence either remained stable or increased up to the year screening was implemented. AAPCs for these countries ranged from -0·2% (95% CI -1·4 to 1·0) to 1·5% (1·1 to 1·8) in men and from -0·5% (-1·7 to 0·6) to 1·2% (0·8 to 1·5) in women. Where high screening coverage and uptake were rapidly achieved (ie, Denmark, the Netherlands, and Slovenia), age-standardised incidence rates initially increased but then subsequently decreased. Conversely, colorectal cancer incidence increased in most countries where no large-scale screening programmes were available (eg, Bulgaria, Estonia, Norway, and Ukraine), with AAPCs ranging from 0·3% (95% CI 0·1 to 0·5) to 1·9% (1·2 to 2·6) in men and from 0·6% (0·4 to 0·8) to 1·1% (0·8 to 1·4) in women. The largest decreases in colorectal cancer mortality were seen in countries with long-standing screening programmes. We observed divergent trends in colorectal cancer incidence, mortality, and stage distribution across European countries, which appear to be largely explained by different levels of colorectal cancer screening implementation. German Cancer Aid (Deutsche Krebshilfe) and the German Federal Ministry of Education and Research.

Sections du résumé

BACKGROUND
Colorectal cancer screening programmes and uptake vary substantially across Europe. We aimed to compare changes over time in colorectal cancer incidence, mortality, and stage distribution in relation to colorectal cancer screening implementation in European countries.
METHODS
Data from nearly 3·1 million patients with colorectal cancer diagnosed from 2000 onwards (up to 2016 for most countries) were obtained from 21 European countries, and were used to analyse changes over time in age-standardised colorectal cancer incidence and stage distribution. The WHO mortality database was used to analyse changes over time in age-standardised colorectal cancer mortality over the same period for the 16 countries with nationwide data. Incidence rates were calculated for all sites of the colon and rectum combined, as well as the subsites proximal colon, distal colon, and rectum. Average annual percentage changes (AAPCs) in incidence and mortality were estimated and relevant patterns were descriptively analysed.
FINDINGS
In countries with long-standing programmes of screening colonoscopy and faecal tests (ie, Austria, the Czech Republic, and Germany), colorectal cancer incidence decreased substantially over time, with AAPCs ranging from -2·5% (95% CI -2·8 to -2·2) to -1·6% (-2·0 to -1·2) in men and from -2·4% (-2·7 to -2·1) to -1·3% (-1·7 to -0·9) in women. In countries where screening programmes were implemented during the study period, age-standardised colorectal cancer incidence either remained stable or increased up to the year screening was implemented. AAPCs for these countries ranged from -0·2% (95% CI -1·4 to 1·0) to 1·5% (1·1 to 1·8) in men and from -0·5% (-1·7 to 0·6) to 1·2% (0·8 to 1·5) in women. Where high screening coverage and uptake were rapidly achieved (ie, Denmark, the Netherlands, and Slovenia), age-standardised incidence rates initially increased but then subsequently decreased. Conversely, colorectal cancer incidence increased in most countries where no large-scale screening programmes were available (eg, Bulgaria, Estonia, Norway, and Ukraine), with AAPCs ranging from 0·3% (95% CI 0·1 to 0·5) to 1·9% (1·2 to 2·6) in men and from 0·6% (0·4 to 0·8) to 1·1% (0·8 to 1·4) in women. The largest decreases in colorectal cancer mortality were seen in countries with long-standing screening programmes.
INTERPRETATION
We observed divergent trends in colorectal cancer incidence, mortality, and stage distribution across European countries, which appear to be largely explained by different levels of colorectal cancer screening implementation.
FUNDING
German Cancer Aid (Deutsche Krebshilfe) and the German Federal Ministry of Education and Research.

Identifiants

pubmed: 34048685
pii: S1470-2045(21)00199-6
doi: 10.1016/S1470-2045(21)00199-6
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1002-1013

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests HDS and NVD are employed by the Belgian Cancer Registry, which is financed by regional and federal authorities for collecting data regarding new cancer diagnoses and cancer screening in Belgium, and for disseminating associated epidemiological parameters. FPf reports having received a research grant from Intuitive Surgery, and payment or honoraria from Amgen (for a lecture) and Intuitive Surgery (for a video presentation), outside the submitted work. All other authors declare no competing interests.

Auteurs

Rafael Cardoso (R)

Division of Preventive Oncology, German Cancer Research Center and National Center for Tumor Diseases, Heidelberg, Germany; Medical Faculty Heidelberg, University of Heidelberg, Heidelberg, Germany.

Feng Guo (F)

Medical Faculty Heidelberg, University of Heidelberg, Heidelberg, Germany; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany.

Thomas Heisser (T)

Medical Faculty Heidelberg, University of Heidelberg, Heidelberg, Germany; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany.

Monika Hackl (M)

Austrian National Cancer Registry, Statistics Austria, Vienna, Austria.

Petra Ihle (P)

Austrian National Cancer Registry, Statistics Austria, Vienna, Austria.

Harlinde De Schutter (H)

Belgian Cancer Registry, Brussels, Belgium.

Nancy Van Damme (N)

Belgian Cancer Registry, Brussels, Belgium.

Zdravka Valerianova (Z)

Bulgarian National Cancer Registry, University Hospital of Oncology, Sofia, Bulgaria.

Trajan Atanasov (T)

Bulgarian National Cancer Registry, University Hospital of Oncology, Sofia, Bulgaria.

Ondřej Májek (O)

Institute of Health Information and Statistics of the Czech Republic, Prague, Czech Republic; Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.

Jan Mužík (J)

Institute of Health Information and Statistics of the Czech Republic, Prague, Czech Republic; Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.

Mef Christina Nilbert (MC)

Danish Cancer Society Research Center, Copenhagen, Denmark; Department of Clinical Medicine, Hvidovre University Hospital, University of Copenhagen, Copenhagen, Denmark.

Anne Julie Tybjerg (AJ)

Danish Cancer Society Research Center, Copenhagen, Denmark.

Kaire Innos (K)

Department of Epidemiology and Biostatistics, National Institute for Health Development, Tallinn, Estonia.

Margit Mägi (M)

Estonian Cancer Registry, National Institute for Health Development, Tallinn, Estonia.

Nea Malila (N)

Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research, Helsinki, Finland.

Anne-Marie Bouvier (AM)

Digestive Cancer Registry of Burgundy, University Hospital of Dijon, INSERM U1231, French Network of Cancer Registries (FRANCIM), Dijon, France.

Véronique Bouvier (V)

Digestive Tumors Registry of Calvados, University Hospital of Caen, U1086 INSERM UCN-ANTICIPE, French Network of Cancer Registries (FRANCIM), Caen, France.

Guy Launoy (G)

Interdisciplinary Research Unit for the Prevention and Treatment of Cancer, Normandy University, University of Caen Normandy, INSERM-ANTICIPE, Caen, France; Department of Research, University Hospital of Caen, Caen, France.

Anne-Sophie Woronoff (AS)

Cancer Registry of Doubs, Centre Hospitalier Régional Universitaire Besançon, Besançon, France.

Mélanie Cariou (M)

Digestive Tumors Registry of Finistère, Centre Hospitalier Régional Universitaire Morvan, French Network of Cancer Registries (FRANCIM), Brest, France.

Michel Robaszkiewicz (M)

Digestive Tumors Registry of Finistère, Centre Hospitalier Régional Universitaire Morvan, French Network of Cancer Registries (FRANCIM), Brest, France.

Patricia Delafosse (P)

Cancer Registry of Isère, French Network of Cancer Registries (FRANCIM), Grenoble, France.

Florence Poncet (F)

Cancer Registry of Isère, French Network of Cancer Registries (FRANCIM), Grenoble, France.

Alexander Katalinic (A)

Cancer Registry of Schleswig-Holstein, Lübeck, Germany.

Paul M Walsh (PM)

National Cancer Registry Ireland, Cork, Ireland.

Carlo Senore (C)

University Hospital 'Città della Salute e della Scienza', SSD Epidemiologia Screening-CPO Piemonte, Turin, Italy.

Stefano Rosso (S)

Piedmont Cancer Registry, Turin, Italy.

Ieva Vincerževskienė (I)

Lithuanian Cancer Registry, National Cancer Institute, Vilnius, Lithuania.

Valery E P P Lemmens (VEPP)

Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands; Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands.

Marloes A G Elferink (MAG)

Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands.

Tom Børge Johannesen (TB)

Cancer Registry of Norway, Oslo, Norway.

Hartwig Kørner (H)

Department of Gastrointestinal Surgery, Stavanger University Hospital, Stavanger, Norway; Department of Clinical Medicine, University of Bergen, Bergen, Norway.

Frank Pfeffer (F)

Department of Clinical Medicine, University of Bergen, Bergen, Norway; Department of Surgery, Haukeland University Hospital, Bergen, Norway.

Maria José Bento (MJ)

Department of Epidemiology, North Region Cancer Registry of Portugal, Portuguese Oncology Institute of Porto, Porto, Portugal; IPO Porto Research Center, Portuguese Oncology Institute of Porto, Porto, Portugal; Department of Population Studies, Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal.

Jessica Rodrigues (J)

Department of Epidemiology, North Region Cancer Registry of Portugal, Portuguese Oncology Institute of Porto, Porto, Portugal; IPO Porto Research Center, Portuguese Oncology Institute of Porto, Porto, Portugal.

Filipa Alves da Costa (F)

Portuguese National Cancer Registry, Portuguese Oncology Institute of Lisbon, Lisbon, Portugal.

Ana Miranda (A)

Portuguese National Cancer Registry, Portuguese Oncology Institute of Lisbon, Lisbon, Portugal.

Vesna Zadnik (V)

Slovenian Cancer Registry, Institute of Oncology, Ljubljana, Slovenia.

Tina Žagar (T)

Slovenian Cancer Registry, Institute of Oncology, Ljubljana, Slovenia.

Arantza Lopez de Munain Marques (A)

Basque Country Cancer Registry, Vitoria-Gasteiz, Spain.

Rafael Marcos-Gragera (R)

Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health Government of Catalonia, Catalan Institute of Oncology, Girona, Spain; Descriptive Epidemiology, Genetics and Cancer Prevention Group, Biomedical Research Institute, Salt, Spain; Consortium for Biomedical Research in Epidemiology and Public Health, Madrid, Spain.

Montse Puigdemont (M)

Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health Government of Catalonia, Catalan Institute of Oncology, Girona, Spain; Descriptive Epidemiology, Genetics and Cancer Prevention Group, Biomedical Research Institute, Salt, Spain.

Jaume Galceran (J)

Tarragona Cancer Registry, Epidemiology and Prevention Cancer Service, Hospital Universitari Sant Joan de Reus, Pere Virgili Health Research Institute, Reus, Spain.

Marià Carulla (M)

Tarragona Cancer Registry, Epidemiology and Prevention Cancer Service, Hospital Universitari Sant Joan de Reus, Pere Virgili Health Research Institute, Reus, Spain.

María-Dolores Chirlaque (MD)

Consortium for Biomedical Research in Epidemiology and Public Health, Madrid, Spain; Tarragona Cancer Registry, Epidemiology and Prevention Cancer Service, Hospital Universitari Sant Joan de Reus, Pere Virgili Health Research Institute, Reus, Spain.

Monica Ballesta (M)

Consortium for Biomedical Research in Epidemiology and Public Health, Madrid, Spain; Department of Epidemiology, Regional Health Council, IMIB-Arrixaca, Murcia University, Murcia, Spain.

Kristina Sundquist (K)

Department of Clinical Sciences, Center for Primary Health Care Research, Lund University, Malmö, Sweden; Department of Family Medicine and Community Health, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Center for Community-based Healthcare Research and Education, Department of Functional Pathology, School of Medicine, Shimane University, Shimane, Japan.

Jan Sundquist (J)

Department of Clinical Sciences, Center for Primary Health Care Research, Lund University, Malmö, Sweden; Department of Family Medicine and Community Health, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Center for Community-based Healthcare Research and Education, Department of Functional Pathology, School of Medicine, Shimane University, Shimane, Japan.

Marco Weber (M)

Cancer Registry Bern-Solothurn, Bern, Switzerland.

Andrea Jordan (A)

Cancer Registry Bern-Solothurn, Bern, Switzerland.

Christian Herrmann (C)

Cancer Registry of Eastern Switzerland and Liechtenstein, St Gallen, Switzerland; Graubünden and Glarus Cancer Registry, Chur, Switzerland.

Mohsen Mousavi (M)

Cancer Registry of Eastern Switzerland and Liechtenstein, St Gallen, Switzerland; Graubünden and Glarus Cancer Registry, Chur, Switzerland.

Anton Ryzhov (A)

National Cancer Registry of Ukraine, National Institute of Cancer, Kyiv, Ukraine; Taras Shevchenko National University of Kyiv, Kyiv, Ukraine.

Michael Hoffmeister (M)

Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany.

Hermann Brenner (H)

Division of Preventive Oncology, German Cancer Research Center and National Center for Tumor Diseases, Heidelberg, Germany; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany; German Cancer Consortium, German Cancer Research Center, Heidelberg, Germany. Electronic address: h.brenner@dkfz.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH